Table 1. Demographic characteristics of responders.
| No. (%) | |||||
|---|---|---|---|---|---|
| Characteristics | Total | PD | Control | P-value | |
| Overall | 71 (100) | 39 (54.9) | 32 (45.0) | ||
| Sex | |||||
| Male | 30 (42.2) | 25 (64.1) | 5 (15.6) | < 0.001 | |
| Female | 41 (57.7) | 14 (35.8) | 27 (84.3) | ||
| Age, y | |||||
| <70 | 25 (35.2) | 11 (15.4) | 14 (19.7) | 0.078 | |
| 70–79 | 33 (46.4) | 18 (46.1) | 15 (46.8) | ||
| >80 | 13 (18.3) | 10 (25.6) | 3 (9.3) | ||
| Living alone | 3 (4.2) | 3 (7.6) | - | 0.109 | |
| Disease duration, years | |||||
| < 5 | 22 (56.4) | - | - | ||
| ≥ 5 | 17 (43.5) | - | - | ||
| HY stage | |||||
| stage 0–2 | 12 (30.7) | - | - | ||
| stage 3, 4 | 27 (69.2) | - | - | ||
| Non-motor symptoms | |||||
| Cognitive impairment | 6 (15.3) | - | - | ||
| Hallucinations | 4 (10.2) | - | - | ||
| RBD | 6 (15.3) | - | - | ||
| L-DOPA, mg | |||||
| < 600 | 30 (76.9) | - | - | ||
| ≥ 600 | 9 (23.0) | - | - | ||
| Other medications | |||||
| Dopamine agonist | 15 (38.4) | - | - | ||
| Psychiatric medicines | 8 (20.5) | - | - | ||
| Sleeping medicines | 13 (33.3) | - | - | ||
| MDS-UPDRS part 2, | 17 (10–20.5) | - | - | ||
| median (IQR), n = 36* | |||||
Abbreviations: HY, Hoehn & Yahr; RBD, REM sleep behavior disorder; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; IQR, interquartile range.
*Of the 39 participants, 36 responded to the question about MDS-UPDRS part 2.